<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10517">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654992</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH B-0608/036-004</org_study_id>
    <nct_id>NCT00654992</nct_id>
  </id_info>
  <brief_title>Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery</brief_title>
  <acronym>EPO-CABG</acronym>
  <official_title>Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether erythropoietin is effective in preventing
      acute kidney dysfunction after coronary artery bypass grafting surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury (AKI) occurs in 7% to 40% of patients undergoing cardiac surgery,
      depending on the definition of AKI used. Even small increments in serum creatinine have been
      shown to be associated with increased mortality after cardiac surgery. However, there are no
      proven interventions to prevent AKI after cardiac surgery. Erythropoietin (EPO) has been
      shown to have tissue-protective effects in various experimental models. In this prospective
      placebo-controlled randomized trial, we evaluated the effectiveness of EPO in the prevention
      of AKI after coronary artery bypass grafting (CABG).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants Who Had AKI (Acute Kidney Injury)</measure>
    <time_frame>at any time within the first 5 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>during the first 5 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Kidney Failure, Acute</condition>
  <arm_group>
    <arm_group_label>EPO group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin-Beta</intervention_name>
    <description>300 IU/kg of EPO or saline intravenously before surgery</description>
    <arm_group_label>EPO group</arm_group_label>
    <other_name>recormon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>300 IU/kg of normal saline intravenously before surgery</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective CABG over age 18

        Exclusion Criteria:

          -  Under age 18

          -  Emergent CABG

          -  Prior exposure to nephrotoxic drug

          -  Dialysis patients

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Young , Na, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>April 28, 2009</lastchanged_date>
  <firstreceived_date>April 4, 2008</firstreceived_date>
  <firstreceived_results_date>March 17, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Ki Young Na/MD PhD</name_title>
    <organization>Department of Internal Medicine</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erythropoietin (EPO) Group</title>
          <description>received 300 U/kg of erythropoietin intraveously following induction of anesthesia</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>received normal saline intraveously following induction of anesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erythropoietin (EPO) Group</title>
          <description>received 300 U/kg of erythropoietin intraveously following induction of anesthesia</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>received normal saline intraveously following induction of anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="71"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="29.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="42.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65" spread="11"/>
                <measurement group_id="B2" value="69" spread="8"/>
                <measurement group_id="B3" value="67" spread="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="18.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="53.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="71.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>estimated glomerular filtration rate (eGFR)as ml/min/1.73m2</description>
        <time_frame>during the first 5 days after surgery</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Erythropoietin (EPO) Group</title>
            <description>received 300 U/kg of erythropoietin intraveously following induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>received normal saline intraveously following induction of anesthesia</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Estimated Glomerular Filtration Rate (eGFR)</title>
            <description>estimated glomerular filtration rate (eGFR)as ml/min/1.73m2</description>
            <units>ml/min/1.73m2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.5" spread="7.3"/>
                  <measurement group_id="O2" value="-9.1" spread="14.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had AKI (Acute Kidney Injury)</title>
        <description>number of participants who had 50% increase in serum creatinine levels from baseline</description>
        <time_frame>at any time within the first 5 days after surgery</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Erythropoietin (EPO) Group</title>
            <description>received 300 U/kg of erythropoietin intraveously following induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>received normal saline intraveously following induction of anesthesia</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Had AKI (Acute Kidney Injury)</title>
            <description>number of participants who had 50% increase in serum creatinine levels from baseline</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Effect of erythropoietin in kidney after cardiac surgery</name_or_title>
      <organization>Seoul National University Bundang Hospital</organization>
      <phone>82-31-787-7014</phone>
      <email>kyna@snubh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
